Comorbidities and outcomes: advancing the field comes at a price.
Comorbidities and outcomes: advancing the field comes at a price.
复制标题
合并症和结果：该领域的进步是有代价的。
DOI：
10.1016/j.bbmt.2011.10.026
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Sorror,MohamedL
中科院分区：
文献类型：
--
作者：
Sorror,MohamedL
来自德国德累斯顿的同事报道了造血细胞移植特异性合并症指数（HCT- ci）在诊断为急性髓系白血病并使用至少9种不同类型的调节方案接受同种异体造血细胞移植（HCT）治疗的患者中的预后影响。作者选择将患者分为HCT-CI评分0（5%）、1-2（21%）和3（74%）。多项分析未能显示HCT-CI评分与非复发死亡率（NRM）或总生存期（OS） bb0之间有统计学意义的关联。在许多先前的研究中，HCT-CI被发现与预后相关[10]。少数与样本量或缺乏足够的合并症数据有关的研究不同意这一观点。德累斯顿研究是第一个具有公平样本量的患者和完整的合并症数据，显示HCT-CI评分和结果之间缺乏相关性的研究。良好样本量的好处相对地被治疗方案的多样性和患者在危险群体中的倾斜分布所抵消。尽管作者认为，不同机构之间社会经济因素的差异可能在一定程度上解释了不一致的结果，但其他原因似乎在这项研究中发挥了更重要的作用。值得关注的两点是，对相关合并症的评估不准确，以及尽管先前的建议[3]，但对患者危险组的分类不平衡。这篇论文包括心脏瓣膜疾病、肝脏合并症和感染的意外高患病率。值得注意的是HCT-CI
Transplantation, colleagues from Dresden, Germany, reported on the prognostic impact of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) among patients diagnosed with acute myeloid leukemia and treated with allogeneic hematopoietic cell transplantation (HCT) using at least 9 different types of conditioning regimens. The authors elected to stratify patients into HCT-CI scores of 0 (5%), 1-2 (21%), and $3 (74%). Multiple analyses failed to show any statistically significant association between the HCT-CI scores and nonrelapse mortality (NRM) or overall survival (OS)[1]. The HCT-CI was found to be associated with outcomes in numerous previous studies [2]. A smaller number of studies with issues related to sample size or lack of sufficient comorbidity data disagreed [2]. The Dresden study is the first with a fair sample size of patients and complete comorbidity data that showed lack of association between HCT-CI scores and outcomes. The benefit of good sample size was relatively offset by multiplicity of regimens and the skewed distribution of patients among risk groups. Although the authors’ suggestion that differences in socioeconomic factors among institutions might, in part, explain the discordant findings is plausible, other reasons seem to play a more prominent role in this study.The 2 points of concern are the inaccurate evaluation of relevant comorbidities and the unbalanced categorization of patients into risk groups despite previous recommendations [3]. The paper included unexpectedly high prevalence of heart valve disease, hepatic comorbidity, and infections. Of note, the HCT-CI
登录
查看更多内容
年龄和合并症的相互作用及其对造血细胞移植 (HCT) 结果的影响
影响因子：
20.3
作者：
F. Ostronoff;B. Storer;R. Storb;S. Bhatia;R. Maziarz;M. Pulsipher;M. Maris;H. Deeg;P. Martin;F. Appelbaum;D. Maloney;B. Sandmaier;M. Sorror
通讯作者：
M. Sorror
DOI：
10.1182/asheducation-2010.1.237
发表时间：
2010-12-01
影响因子：
3
作者：
Sorror, Mohamed L.
通讯作者：
Sorror, Mohamed L.
影响因子：
4.3
作者：
Birninger, Nicole;Bornhaeuser, Martin;Schetelig, Johannes
通讯作者：
Schetelig, Johannes
造血细胞移植合并症指数 (HCT-CI) 对 HCT 结果的预测能力的多机构验证
影响因子：
20.3
作者：
M. Sorror;F. Ostronoff;R. Storb;S. Bhatia;R. Maziarz;M. Pulsipher;M. Maris;H. Deeg;P. Martin;F. Appelbaum;D. Maloney;B. Sandmaier;B. Storer
通讯作者：
B. Storer